These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1075 related articles for article (PubMed ID: 33569983)

  • 1. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
    Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
    Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES
    J Thorac Oncol; 2022 Dec; 17(12):1404-1414. PubMed ID: 36096442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X; Zhou Z; Zeng X; Peng L; Liu Q
    Front Public Health; 2022; 10():985834. PubMed ID: 36211665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
    J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    Zhao M; Shao T; Shao H; Zhou C; Tang W
    BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparisons of brigatinib and alectinib for front-line
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
    Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
    Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
    Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G; Tazza M; Matocci R; Chiari R; Crinò L
    Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
    Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
    Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
    Nishio M; Murakami H; Horiike A; Takahashi T; Hirai F; Suenaga N; Tajima T; Tokushige K; Ishii M; Boral A; Robson M; Seto T
    J Thorac Oncol; 2015 Jul; 10(7):1058-66. PubMed ID: 26020125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.